Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before. The Thermo Scientific™ Glacios™ 3 Cryo-TEM offers researchers the next major advancement in 200 kV imaging and structural analysis. Cryogenic electron microscopy (cryo-EM), an ad

Incheon, S. Korea and Maryland, United States, March 31, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States. The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, sup

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlik

Shimadzu Scientific Instruments (SSI, Columbia, Maryland, USA), a Shimadzu Group company, has opened its new research and development (R&D) facility in South San Francisco, California. Since April 2024, SSI has been enhancing its R&D division with a focus on developing analytical instruments, software, applications, and lab automation solutions tailored to the needs of pharmaceutical and life science customers in North America. The San Francisco Bay Area is a premi

Bioptimus, a global AI company building the world's first world model for biology, today announced the launch of its Spatial Tissue Embedding Learning Atlas (STELA), a multinational spatial data generation initiative anchored by a partnership with 10x Genomics, Inc. (Nasdaq: TXG) and Broad Clinical Labs. While foundation models for language have thrived on vast digital datasets, biology has long lacked the standardized, high-quality data scale required for a similar breakthrough

UK Biotech Day 2026, taking place on 27–28 May 2026, will be held at the Radisson Hotel & Conference Centre London Heathrow. The event is set to spotlight the strength, global relevance, and collaborative spirit of the UK’s biotechnology ecosystem. It will bring together leaders from industry, research, government, and investment to share ideas, explore new opportunities, and shape the future of life sciences. UK Biotech Day is designed to spark meaningful conversati

CPHI Celebration awards recognises exceptional enterprises across eight comprehensive categories spanning the entire pharmaceutical industry chain, fully showcasing the outstanding achievements in the pharma industry.  Winning enterprises are invited to attend the exclusive CPHI Celebration awards & Networking party on the evening of 16 June 2026. Apply now and join us for a prestigious evening of networking, connecting and celebrating where pharmaceutical excelle

insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS. BMS has nominated two additional targets, ALS-2 and ALS-3, which were iden

SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas. The U.S. Food and Drug Administration (FDA) carried out a general inspection of the site from February 9 to February 12, 2026. After a thorough review of the facility’s quality systems and manufacturing operations, the FDA completed the inspection without issuing a Form 483. This “No Action Indicated” (NAI) status confir

Researchers from Southern Cross University (SCU), in partnership with the Melbourne Integrative Oncology Group (MIOG), are launching an Australian-first clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment for high-grade glioma brain cancer. Backed by a $1 million gift from an anonymous donor, the collaborative research will examine whether delivering oxygen in a pressurised environment during active cancer treatment